Haisco Pharmaceutical Group Co., Ltd. (002653.SZ): BCG Matrix [Apr-2026 Updated]

Haisco sits at a pivotal moment: blockbuster anesthetic Ciprofol and newly NRDL-listed metabolic drugs are driving high-growth 'stars' while cash-rich parenteral nutrition and liver treatments fund an aggressive R&D push (R&D ~27% of revenue) into ambitious oncology and respiratory 'question marks'-even as legacy antibiotics and cardiovascular generics are being deprioritized or eyed for exit; how management reallocates cash from mature cash cows to selectively fund trials or partner to derisk will determine whether these pipelines become the group's next engines of growth.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) - BCG Matrix Analysis: Stars

Ciprofol series - Star product in intravenous anesthesia. Ciprofol, a proprietary Class 1 innovative anesthetic, continued to expand rapidly through 2024-2025 and is projected to contribute over 35% of total group sales in 2025. In 2024 the narcotics segment recorded a year‑on‑year increase of 44.96%, with Ciprofol‑related sales reaching 1.232 billion yuan. By December 2025 Ciprofol had secured over 20% share of the domestic propofol‑alternative market, supported by inclusion in the National Reimbursement Drug List (NRDL). The relevant global anesthetic agent market is expanding at a CAGR of 5.4%, underpinning Haisco's international expansion plans and positioning Ciprofol as a sustained high‑growth, high‑share business unit.

Innovative metabolic disease therapies - Emerging star cluster. Newly approved products Coglitin tablets and Cligabarin benzenesulfonate capsules were approved mid‑2024 and included in NRDL by January 2025, enabling rapid reimbursement‑driven volume uptake. The metabolic therapy segment is operating in a market growing at an estimated 7.2% annually. Haisco reported semi‑annual revenue growth of 19% in 2025 for the group, with the company reaching 2.00 billion yuan in the first half of 2025, reflecting strong contribution from these specialty launches. The global metabolic drug market is estimated at ~150 billion USD, creating significant headroom for Haisco to capture double‑digit shares in targeted sub‑segments by 2026.

R&D, CAPEX and commercial scaling - resource allocation typical of Stars. Haisco's reported R&D intensity was 26.90% of revenue in late 2024, with R&D spend heavily weighted toward expanding Ciprofol indications (pediatric anesthesia, ICU sedation) and accelerating commercialization of metabolic assets. Concurrently, elevated CAPEX is being deployed for production scale‑up and commercial infrastructure to support large‑volume NRDL‑driven demand.

Key growth drivers for Star products:

• NRDL inclusion accelerating reimbursement and volume uptake for Ciprofol, Coglitin and Cligabarin.
• High R&D intensity (26.90% of revenue) targeting new indications and lifecycle expansion.
• Strong domestic market penetration (>20% for Ciprofol) and structured international expansion aligned with 5.4% global market CAGR.
• Elevated CAPEX to expand manufacturing capacity and commercial footprint for specialty metabolic drugs.

Operational and financial priorities to sustain Star status:

• Complete pediatric and ICU sedation indication trials for Ciprofol to expand addressable market and extend NRDL reimbursement scope.
• Scale commercial production lines to meet NRDL‑driven demand and export requirements; maintain quality compliance for overseas filings.
• Drive market access and physician adoption programs for Coglitin and Cligabarin to achieve targeted double‑digit shares by 2026.
• Preserve R&D intensity while balancing margin recovery as volumes scale; monitor CAPEX returns via unit economics and payback timelines.

Performance monitoring KPIs for Stars:

• Market share (% domestic and target export markets) - monthly/quarterly tracking.
• Revenue contribution by product - Ciprofol % of group sales and metabolic product revenue curve.
• R&D spend allocation and clinical milestone delivery dates for indication expansions.
• Manufacturing utilization rate, unit cost trends, and CAPEX‑to‑revenue payback period.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) - BCG Matrix Analysis: Cash Cows

Cash Cows

Parenteral nutrition drug portfolio remains the company's primary cash generator with a stable market share that ranks among the top in China as of late 2025. Flagship products such as Polyene Phosphatidylcholine Injection and the Fat‑soluble Vitamin series deliver consistently high gross margins near the group average of 71.46%. The global parenteral nutrition market is mature, growing at an estimated 4.6% annually; Haisco's mature position yields predictable volumes and pricing stability. The segment benefits from an established commercial footprint covering over 10,000 Grade II and above hospitals, a low incremental CAPEX requirement, and free cash flow that is reallocated to R&D and strategic investment. Predictable revenue and profits from these products supported a 2024 net profit of 395 million yuan, underpinning group liquidity and debt service capacity.

Established liver disease treatments maintain a strong defensive position as Haisco ranks fifth largest manufacturer in this therapeutic area in China as of December 2025. These mature generics and branded generics exhibit high brand loyalty and are embedded in domestic treatment guidelines for digestive and anti‑infection care, producing steady, low‑volatility sales. With low market growth in traditional liver generics, the unit emphasizes operational efficiency and cost control to maximize return on invested capital. The segment contributed materially to the group's trailing twelve‑month revenue of 592 million USD reported in late 2025 and provides recurring cash flows used to fund Phase III trials for respiratory and oncology candidates.

Primary uses of cash generated by Cash Cows

• Fund Phase III clinical trials for respiratory and oncology candidates (direct trial expenses, CRO fees, patient enrollment costs).
• Support innovative R&D programs (preclinical and early clinical stages, formulation development).
• Maintain manufacturing quality and compliance (GMP upkeep, regulatory submissions) with limited CAPEX.
• Cover working capital and debt servicing to preserve financial flexibility.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) - BCG Matrix Analysis: Question Marks

Dogs - Question Marks: Haisco's oncology and immunology pipeline contains multiple Category 1 new molecular entities currently positioned as high-growth/low-share assets (BCG "Question Marks"). As of December 2025 these include HSK47388 (psoriasis) and HSK41959 (advanced solid tumors) in Phase I/II, each with zero commercial market share but targeting a global oncology and immunology market projected to exceed USD 250.0 billion by 2028. Cumulative R&D investment allocated to these programs and related discovery efforts exceeded RMB 1.0 billion in 2024; total program budgets through pivotal readouts are estimated at RMB 1.6-2.4 billion per asset depending on trial design and regulatory requirements.

Clinical and regulatory timelines are concentrated in 2026-2027 for pivotal data readouts and first regulatory filings; success is binary and contingent on safety/efficacy endpoints. Haisco's stated strategy is selective internal funding to advance a subset of these candidates while preserving capital flexibility to out-license assets that do not meet pre-specified go/no-go criteria.

Respiratory portfolio: HSK31858 tablets for non-cystic fibrosis bronchiectasis are in Phase III domestic clinical research as of late 2025. This indication targets an underserved segment of China's respiratory market, estimated at RMB 45-60 billion annually with double-digit CAGR in selected subsegments. The program currently generates no revenue and is supported by a dedicated portion of Haisco's 810-person R&D organization. Management has allocated clinical operations, regulatory affairs, and biostatistics resources specifically to accelerate an NDA submission.

Risk and resource profile for these Question Marks:

• Market share: 0% current commercialization for listed assets; high potential addressable populations but intense competition from multinational incumbents.
• Capital intensity: incremental R&D outlays per program estimated at RMB 0.2-2.4 billion to reach regulatory decision depending on size/complexity of pivotal trials.
• Clinical risk: binary dependency on Phase II/III readouts; median time to first pivotal readout 12-24 months from late-2025.
• Strategic options: selective internal investment, external co-development, out-licensing for later-stage programs, or divestment of low-probability assets.

Operational implications for portfolio management include prioritization rules, go/no-go decision gates tied to interim efficacy/safety thresholds, and contingency funding plans. Key measurable triggers for reclassification from Question Mark to Star (or to Dog if deprioritized) are positive pivotal data, first regulatory filing, or successful out-license terms that de-risk balance-sheet exposure.

Haisco Pharmaceutical Group Co., Ltd. (002653.SZ) - BCG Matrix Analysis: Dogs

Dogs

Legacy generic antibiotics (Cefoperazone Sodium; Tazobactam Sodium): As of December 2025 these older injectable cephalosporin combinations operate in a low-growth, highly fragmented market under significant pricing compression driven by China's volume-based procurement (VBP). Annual unit volumes remain sizable (estimated 18-22 million vials/year for the combined lines) but average selling price (ASP) declines of 20-35% since 2023 have reduced gross margins from historical levels around 48% to current mid-20s percentage points on the oldest SKUs. Revenue contribution from these legacy antibiotics to consolidated revenue is estimated at 7.5% in FY2024, declining to an estimated 5.6% in FY2025. Management has deprioritized these assets in favor of 'first generic' protected launches; likely actions include selective divestment, phased manufacturing exits, or converting capacity to contract manufacturing for higher-margin lines.

Traditional cardiovascular generics: By late 2025 the company's older cardiovascular molecules (ACE inhibitors, beta-blocker generics and certain fixed-dose combinations) sit in a mature, low-growth therapeutic area where market expansion is limited by regulatory pricing caps and strong competition from low-cost domestic manufacturers. Haisco's relative market share across core cardiovascular generics is estimated at 6-9% versus category leaders at 18-30%. The contribution of cardiovascular generics to net profit has fallen-estimated operating margin compression from ~22% in 2021 to ~8-12% in 2025-partly because R&D spend rose to 16.77% of sales to support innovative pipelines and 'first generic' projects, shifting corporate resource allocation away from legacy lines. Ongoing fixed overhead and regulatory compliance costs make small-margin continuation uneconomical; management signals favor portfolio rationalization, outsourcing, or selective licensing out of older cardiovascular SKUs.

Common characteristics of the 'Dogs' segment within Haisco's portfolio include:

• Low to zero market growth and downward pricing trends under VBP and national reimbursement controls.
• Low relative market share versus category leaders for matured therapeutic areas.
• Compressing gross and operating margins driven by ASP erosion and sustained overhead.
• Limited strategic fit with the group's shift toward protected, innovation-linked 'first generic' launches and specialty therapies.

Operational and portfolio actions being executed or considered (late 2025):

• Phase-out schedule for the oldest antibiotic SKUs with <1% contribution to EBITDA within 24 months.
• Assessment of contract manufacturing conversion for facilities producing low-margin cardiovascular generics to reduce fixed-cost burden; target capacity reallocation of 15-25% by 2026.
• Selective divestiture or licensing of legacy lines where buyer economics are favorable; target disposal pipeline of 5-8 SKUs through 2026.
• Reinvestment of freed cashflow into R&D and protected first-generic launches, maintaining the group's R&D ratio near 16-17% through 2026.